NTRA:NGS-Natera Inc. (USD)

EQUITY | Diagnostics & Research | Nasdaq Global Select

Last Closing

USD 172.61

Change

+3.23 (+1.91)%

Market Cap

USD 0.67B

Volume

1.20M

Analyst Target

USD 56.20
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Natera Inc is a diagnostics company with proprietary molecular and bioinformatics technology that it is deploying to change the management of genetic disease.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-02-19 )

Largest Industry Peers for Diagnostics & Research

Symbol Name Price(Change) Market Cap
IDXX IDEXX Laboratories Inc

+1.87 (+0.41%)

USD 34.56B
ILMN Illumina Inc

-5.80 (-5.63%)

USD 21.05B
ICLR ICON PLC

+10.52 (+5.50%)

USD 16.55B
MEDP Medpace Holdings Inc

+0.89 (+0.26%)

USD 10.85B
EXAS EXACT Sciences Corporation

-0.97 (-1.92%)

USD 9.13B
GH Guardant Health Inc

-1.60 (-3.27%)

USD 5.49B
RDNT RadNet Inc

-1.64 (-2.55%)

USD 4.54B
SHC Sotera Health Co

-0.11 (-0.81%)

USD 3.91B
VCYT Veracyte Inc

-1.06 (-2.52%)

USD 3.40B
TWST Twist Bioscience Corp

-2.90 (-6.04%)

USD 3.12B

ETFs Containing NTRA

CURG:LSE VanEck Genomics and Healt.. 6.13 % 0.00 %

-0.24 (-5.90%)

USD 5.28M
PTH Invesco DWA Healthcare Mo.. 6.13 % 0.60 %

-0.63 (-5.90%)

USD 0.13B
GNOG:LSE Global X Genomics & Biote.. 6.05 % 0.00 %

-0.08 (-5.90%)

USD 9.83M
GN0M:XETRA 5.84 % 0.00 %

N/A

N/A
GNOM:SW Global X Genomics & Biote.. 5.84 % 0.00 %

-0.06 (-5.90%)

USD 9.83M
EKG First Trust Nasdaq Lux Di.. 5.37 % 0.00 %

-0.21 (-5.90%)

USD 2.77M
ARCG:LSE ARK Genomic Revolution UC.. 4.97 % 0.00 %

-28.50 (-5.90%)

USD 5.84M
ARKG:LSE ARK Genomic Revolution UC.. 4.97 % 0.00 %

-0.33 (-5.90%)

USD 5.84M
CURE:XETRA 4.55 % 0.00 %

N/A

N/A
WBIO:LSE WisdomTree BioRevolution .. 4.22 % 0.00 %

-18.90 (-5.90%)

USD 3.82M
WDNA WisdomTree BioRevolution .. 4.11 % 0.00 %

-0.16 (-5.90%)

USD 2.27M
WRNA:XETRA 4.11 % 0.00 %

N/A

N/A
CURE:AU ETFS S&P Biotech ETF 2.35 % 0.00 %

+0.60 (+-5.90%)

USD 0.04B
WDNA:LSE WisdomTree BioRevolution .. 2.31 % 0.00 %

-0.15 (-5.90%)

N/A
HEAL:SW iShares Healthcare Innova.. 2.18 % 0.00 %

+0.01 (+-5.90%)

N/A
ZUH:CA BMO Equal Weight US Healt.. 1.97 % 0.39 %

+0.33 (+-5.90%)

CAD 0.22B
DOCG:LSE L&G Healthcare Breakthrou.. 1.85 % 0.00 %

-5.40 (-5.90%)

USD 0.07B
DOCT:LSE L&G Healthcare Breakthrou.. 1.85 % 0.00 %

-0.04 (-5.90%)

USD 0.07B
XMLH:F 1.80 % 0.00 %

N/A

N/A
DOCT:SW L&G Healthcare Breakthrou.. 1.80 % 0.00 %

-0.08 (-5.90%)

USD 0.07B
LABU Direxion Daily S&P Biotec.. 1.69 % 1.14 %

+0.55 (+-5.90%)

USD 0.77B
VBK Vanguard Small-Cap Growth.. 0.74 % 0.07 %

-3.18 (-5.90%)

USD 20.34B
VISM:AU Vanguard MSCI Internation.. 0.24 % 0.00 %

-0.60 (-5.90%)

USD 0.29B
WOSC:SW SPDR® MSCI World Small C.. 0.23 % 0.00 %

-1.02 (-5.90%)

USD 0.99B
ARKG ARK Genomic Revolution ET.. 0.00 % 0.75 %

-1.25 (-5.90%)

USD 1.32B
BBH VanEck Biotech ETF 0.00 % 0.35 %

+1.08 (+-5.90%)

USD 0.40B
FHH:CA First Trust AlphaDEX US H.. 0.00 % 0.77 %

+0.57 (+-5.90%)

CAD 0.01B
FXH First Trust Health Care A.. 0.00 % 0.63 %

-0.04 (-5.90%)

USD 1.05B
IBB iShares Biotechnology ETF 0.00 % 0.47 %

+0.69 (+-5.90%)

USD 6.39B
BTEC 0.00 % 0.42 %

N/A

N/A
EDGE:CA Evolve Innovation Index F.. 0.00 % 0.60 %

-0.61 (-5.90%)

CAD 0.04B
ZHU:CA BMO Equal Weight US Healt.. 0.00 % 0.00 %

+0.01 (+-5.90%)

CAD 0.01B
FSMD Fidelity Small-Mid Factor 0.00 % 0.00 %

-0.45 (-5.90%)

USD 0.81B
WLDS:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.08 (-5.90%)

N/A
WSML:LSE iShares MSCI World Small .. 0.00 % 0.00 %

-0.06 (-5.90%)

N/A
IS0R:F 0.00 % 0.00 %

N/A

N/A
ZPRS:F 0.00 % 0.00 %

N/A

N/A
2B78:XETRA 0.00 % 0.00 %

N/A

N/A
IS0R:XETRA 0.00 % 0.00 %

N/A

N/A
IUSN:XETRA 0.00 % 0.00 %

N/A

N/A
ZPRS:XETRA 0.00 % 0.00 %

N/A

N/A
XMLH:XETRA 0.00 % 0.00 %

N/A

N/A
BBMC JPMorgan BetaBuilders U.S.. 0.00 % 0.00 %

-0.95 (-5.90%)

USD 1.99B
BKMC BNY Mellon US Mid Cap Cor.. 0.00 % 0.00 %

-0.94 (-5.90%)

USD 0.55B
QQQJ Invesco NASDAQ Next Gen 1.. 0.00 % 0.00 %

-0.23 (-5.90%)

USD 0.68B
EDGE-U:CA Evolve Innovation Index F.. 0.00 % 0.00 %

-0.03 (-5.90%)

N/A
FRTY Alger Mid Cap 40 ETF 0.00 % 0.00 %

-0.30 (-5.90%)

USD 0.09B
FHH-F:CA First Trust AlphaDEX U.S... 0.00 % 0.00 %

N/A

CAD 0.01B
ATFV Alger 35 ETF 0.00 % 0.00 %

-0.46 (-5.90%)

USD 0.03B
2B78:F 0.00 % 0.00 %

N/A

N/A
CVRT Calamos ETF Trust 0.00 % 0.00 %

-0.78 (-5.90%)

USD 0.01B

Market Performance

  Market Performance vs. Industry/Classification (Diagnostics & Research) Market Performance vs. Exchange (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.04% 68% D+ 75% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.04% 68% D+ 75% C
Trailing 12 Months  
Capital Gain 147.43% 90% A- 95% A
Dividend Return N/A N/A N/A N/A N/A
Total Return 147.43% 90% A- 95% A
Trailing 5 Years  
Capital Gain 365.13% 100% F 96% N/A
Dividend Return N/A N/A N/A N/A N/A
Total Return 365.13% 100% F 96% N/A
Average Annual (5 Year Horizon)  
Capital Gain 49.43% 84% B 87% B+
Dividend Return 49.43% 84% B 87% B+
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 90.29% 37% F 23% F
Risk Adjusted Return 54.75% 94% A 80% B-
Market Capitalization 0.67B 98% N/A 96% N/A

Key Financial Ratios

  Ratio vs. Industry/Classification (Diagnostics & Research) Ratio vs. Market (Nasdaq Global Select)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio N/A N/A N/A
Price/Book Ratio 26.59 5% 6%
Price / Cash Flow Ratio -94.58 98% 97%
Price/Free Cash Flow Ratio -26.80 95% 95%
Management Effectiveness  
Return on Equity -25.82% 61% 41%
Return on Invested Capital -40.66% 51% 27%
Return on Assets -9.96% 53% 34%
Debt to Equity Ratio 36.97% 50% 48%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Superior Revenue Growth

This stock has shown top quartile revenue growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Highly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Negative free cash flow

The company had negative total free cash flow in the most recent four quarters.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector